Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Primary Target | Pathway | Mean Normalized Growth Rate Inhibition Value | Increased Fraction Dead |
|---|---|---|---|---|---|---|
| T47D | Palbociclib | 0.031623 | CDK4/6 | Cell cycle | 0.4646 | 0.00870 |
| T47D | Abemaciclib | 10.0 | CDK4/6 | Cell cycle | -0.0412 | 0.10529 |
| T47D | Abemaciclib | 3.1623 | CDK4/6 | Cell cycle | 0.0494 | 0.06623 |
| T47D | Trametinib | 0.00031623 | MEK | MAPK/nRTK | 0.9443 | 0.00270 |
| T47D | Etoposide | 3.1623 | Topo II | Chemotherapy | -0.1861 | 0.14904 |
| T47D | Dasatinib | 3.1623 | BCR/ABL | MAPK/nRTK | 0.6769 | 0.01819 |
| T47D | Dasatinib | 0.01 | BCR/ABL | MAPK/nRTK | 0.9173 | -0.00101 |
| T47D | Etoposide | 10.0 | Topo II | Chemotherapy | -0.1776 | 0.18272 |
| T47D | Dasatinib | 10.0 | BCR/ABL | MAPK/nRTK | 0.4961 | 0.01864 |
| T47D | Doxorubicin | 0.001 | Chemo | Chemotherapy | 0.7842 | 0.00725 |